Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC

Open source

DOI: 10.1200/jco-25-02255
Published: 2026 Aug 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-02255,
  title = {Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.},
  author = {Tung N and Zhao F and DeMichele A and Prat A and Winer EP and Wright JL and Recht A and Weiss AC and Tjoe JA and Feldman SM and Rocque GB and Smith ML and O'Sullivan CC and Sardesai SD and Tang SC and Modi S and Irvin WJ and Unni N and Battelli C and Bagegni N and Krie AK and George MA and Telli ML and Borges VF and D'Abreo N and Shah P and Villagrasa P and Badve S and Partridge AH and Miller KD and Carey LA and Wolff AC},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-02255},
  url = {https://doi.org/10.1200/jco-25-02255}
}

RIS

TY  - JOUR
TI  - Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
AU  - Tung N
AU  - Zhao F
AU  - DeMichele A
AU  - Prat A
AU  - Winer EP
AU  - Wright JL
AU  - Recht A
AU  - Weiss AC
AU  - Tjoe JA
AU  - Feldman SM
AU  - Rocque GB
AU  - Smith ML
AU  - O'Sullivan CC
AU  - Sardesai SD
AU  - Tang SC
AU  - Modi S
AU  - Irvin WJ
AU  - Unni N
AU  - Battelli C
AU  - Bagegni N
AU  - Krie AK
AU  - George MA
AU  - Telli ML
AU  - Borges VF
AU  - D'Abreo N
AU  - Shah P
AU  - Villagrasa P
AU  - Badve S
AU  - Partridge AH
AU  - Miller KD
AU  - Carey LA
AU  - Wolff AC
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-02255
UR  - https://doi.org/10.1200/jco-25-02255
ER  -

APA

N, T., F, Z., A, D., A, P., EP, W., JL, W., A, R., AC, W., JA, T., SM, F., GB, R., ML, S., CC, O., SD, S., SC, T., S, M., WJ, I., N, U., C, B., N, B., AK, K., MA, G., ML, T., VF, B., N, D., P, S., P, V., S, B., AH, P., KD, M., LA, C., & AC, W. (2026). Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-02255

Source records

pubmed · retrieved 2026-09-25T23:24:00.037Z
europe-pmc · retrieved 2026-09-25T23:24:00.048Z